Key Points
- Director Melissa Starovasnik sold 1,000 shares on April 1 at an average price of $51.00 under a pre-arranged Rule 10b5-1 plan, trimming her position by 3.74% to 25,722 shares (about $1.31M).
- Recent results show growth but continued losses: Q4 revenue rose 16.9% YoY to $103.7M, but EPS was -$0.50 (missing estimates) and the company remains unprofitable with negative net margin and ROE.
- Market and analyst view: TWST trades near $50 with a $3.08B market cap and a consensus "Moderate Buy" rating (average target $46.50), while several analysts have recently raised targets into the $50–$55 range.
Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) Director Melissa Starovasnik sold 1,000 shares of the stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $51.00, for a total transaction of $51,000.00. Following the transaction, the director directly owned 25,722 shares in the company, valued at $1,311,822. The trade was a 3.74% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Twist Bioscience Price Performance
NASDAQ:TWST opened at $50.21 on Friday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.37 and a current ratio of 3.78. The company has a market capitalization of $3.08 billion, a price-to-earnings ratio of -39.23 and a beta of 2.20. Twist Bioscience Corporation has a one year low of $23.30 and a one year high of $57.88. The stock has a 50-day simple moving average of $46.99 and a 200 day simple moving average of $37.29.
Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its quarterly earnings data on Monday, February 2nd. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.02). Twist Bioscience had a negative net margin of 19.56% and a negative return on equity of 27.16%. The firm had revenue of $103.70 million for the quarter, compared to analyst estimates of $100.32 million. The business's quarterly revenue was up 16.9% compared to the same quarter last year. Sell-side analysts predict that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.
Institutional Trading of Twist Bioscience
Several hedge funds have recently made changes to their positions in TWST. Rockefeller Capital Management L.P. boosted its position in Twist Bioscience by 28.9% during the 4th quarter. Rockefeller Capital Management L.P. now owns 14,970 shares of the company's stock valued at $475,000 after purchasing an additional 3,359 shares during the period. Axxcess Wealth Management LLC acquired a new stake in Twist Bioscience in the fourth quarter worth $201,000. Mercer Global Advisors Inc. ADV acquired a new stake in Twist Bioscience in the fourth quarter worth $242,000. Empowered Funds LLC bought a new stake in Twist Bioscience in the fourth quarter valued at $58,000. Finally, VARCOV Co. bought a new stake in Twist Bioscience in the fourth quarter valued at $263,000.
Analysts Set New Price Targets
Several equities research analysts recently issued reports on TWST shares. Guggenheim upped their price target on Twist Bioscience from $50.00 to $55.00 and gave the company a "buy" rating in a research report on Monday, March 30th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Twist Bioscience in a research note on Friday, March 27th. Barclays increased their target price on shares of Twist Bioscience from $39.00 to $50.00 and gave the stock an "overweight" rating in a report on Tuesday, February 3rd. Robert W. Baird set a $50.00 price target on shares of Twist Bioscience in a research report on Tuesday, February 3rd. Finally, TD Cowen reaffirmed a "buy" rating on shares of Twist Bioscience in a report on Thursday, January 8th. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $46.50.
Read Our Latest Stock Analysis on TWST
Twist Bioscience Company Profile
(
Get Free Report)
Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.
At the core of Twist's offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
